Program
belantamab mafodotin
Also written as “Belantamab mafodotin”, “Belantamab Mafodotin” and “GSK2857916”.
Its studies are mostly in Multiple Myeloma · Amyloidosis, led by GlaxoSmithKline.
Drug pageBelantamab mafodotin: every studyAll 56 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 2518 open or running | phase 3since Nov 11, 2019 | Feb 13, 2014 | Aug 3, 2028phase 2 · NCT05714839 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 6 earlier studies, Feb 13, 2014 to Jan 27, 2020.
- Dec 9, 2017Named belantamab mafodotinINNProposed as its International Nonproprietary Name in WHO's List 118 · before, GSK2857916
- May 19, 20202 phase 1 studies in Multiple MyelomaNCT04398745, NCT04398680
- Jul 21, 2020Phase 3 study in Multiple MyelomaNCT04484623 · 302 enrolled · United States, Australia, Brazil and more
- Sep 8, 2020Phase 3 study in Multiple MyelomaNCT04549363 · 16 enrolled · United States
- Sep 22, 2021Phase 2 study in Multiple MyelomaNCT05064358 · 177 enrolled · United States, Argentina, Australia and more
- Jan 27, 2023Phase 2 study in Multiple MyelomaNCT05714839 · 123 planned · United States, Argentina, Australia and more
- Oct 22, 2024Phase 2 study in Multiple MyelomaNCT06655818 · 4 enrolled · France, Korea, Republic of
- Nov 6, 2024Phase 3 study in Multiple MyelomaNCT06679101 · 520 planned · United States, Argentina, Australia and more
- Mar 6, 20252 phase 3 studies in Multiple MyelomaNCT06868667, NCT06868654
- Apr 25, 2025Phase 3 study in Multiple MyelomaNCT06956170 · 21 enrolled · Japan
- Jul 22, 2025Phase 2 study in Multiple MyelomaNCT07084896 · 106 enrolled · United States, Australia, Canada and more
- Aug 25, 20252 phase 2 studies in Multiple MyelomaNCT07150104, NCT07150091
- Oct 13, 20253 phase 2 studiesNCT07217184, NCT07217119, NCT07224672
- May 20, 2026Phase 1 study in Multiple MyelomaNCT07609706 · 20 planned
- May 21, 2026Phase 2 study in Multiple MyelomaNCT07614360 · 150 planned
Ahead
- Aug 3, 2028Primary completion: phase 2 study in Multiple MyelomaNCT05714839
- Feb 28, 2029Primary completion: phase 2 study in Multiple MyelomaNCT07614360
- Apr 28, 2031Primary completion: phase 3 study in Multiple MyelomaNCT06679101
- Aug 22, 2031Primary completion: phase 1 study in Multiple MyelomaNCT07609706
TargetBeta
“An antibody-drug conjugate (ADC) consisting of belantamab, an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA), ”NCIt, by rule
“Tumor necrosis factor receptor superfamily member 17 binding agent”ChEMBL 37, by rule
Other programs on TNFRSF17
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elranatamabrule | Pfizer | phase 4 | 15 |
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 13 |
| teclistamabrule | Johnson & Johnson | phase 4 | 11 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| etentamig | AbbVie | phase 3 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 8 |
| anitocabtagene autoleucelrule | Gilead Sciences | phase 3 | 6 |
| equecabtagene autoleucelrule | nanjing-iaso-biotechnology-co-ltd | phase 3 | 5 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| Evarucabgene Autoleucelrule | nexcella-inc | phase 3 | 2 |
| Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytesrule | cartesian-therapeutics | phase 2 | 6 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07614360Multiple Myeloma | 2 | Not yet recruiting | Feb 28, 2029 | 150 |
| NCT07609706Multiple Myeloma | 1 | Not yet recruiting | Aug 22, 2031 | 20 |
| NCT07224672Amyloidosis · United States, Australia, United Kingdom | 2 | Recruiting | Jan 12, 2033 | 60 |
| NCT07217184Multiple Myeloma · United States, Australia, Brazil and more | 2 | Active, not recruiting | Apr 17, 2025 | 30 |
| NCT07217119Multiple Myeloma · United States, Australia, Canada and more | 2 | Active, not recruiting | Apr 17, 2025 | 25 |
| NCT07150104Multiple Myeloma · Brazil, Canada, France and more | 2 | Active, not recruiting | Apr 17, 2025 | 14 |
| NCT07150091Multiple Myeloma · United States, Brazil, Canada and more | 2 | Active, not recruiting | Apr 17, 2025 | 20 |
| NCT07084896Multiple Myeloma · United States, Australia, Canada and more | 2 | Active, not recruiting | Apr 17, 2025 | 106 |
| NCT06956170Multiple Myeloma · Japan | 3 | Active, not recruiting | May 27, 2024 | 21 |
| NCT06868667Multiple Myeloma · Japan | 3 | Active, not recruiting | Apr 3, 2024 | 24 |
| NCT06868654Multiple Myeloma · China | 3 | Active, not recruiting | Apr 3, 2024 | 72 |
| NCT06679101Multiple Myeloma · United States, Argentina, Australia and more | 3 | Recruiting | Apr 28, 2031 | 520 |
| NCT06655818Multiple Myeloma · France, Korea, Republic of | 2 | Terminated | Feb 14, 2024 | 4 |
| NCT05714839Multiple Myeloma · United States, Argentina, Australia and more | 2 | Recruiting | Aug 3, 2028 | 123 |
| NCT05064358Multiple Myeloma · United States, Argentina, Australia and more | 2 | Completed | Aug 19, 2024 | 177 |
| NCT04549363Multiple Myeloma · United States | 3 | Terminated | Nov 21, 2022 | 16 |
| NCT04484623Multiple Myeloma · United States, Australia, Brazil and more | 3 | Active, not recruiting | Jan 29, 2024 | 302 |
| NCT04398745Multiple Myeloma · Greece, South Korea | 1 | Active, not recruiting | Apr 21, 2025 | 36 |
| NCT04398680Multiple Myeloma · United States, Greece, South Korea | 1 | Withdrawn | Nov 4, 2025 | 0 |
| NCT04246047Multiple Myeloma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Oct 2, 2023 | 494 |
| NCT04177823Multiple Myeloma · China | 1 | Completed | Dec 30, 2021 | 6 |
| NCT04162210Multiple Myeloma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Sep 12, 2022 | 325 |
| NCT04091126Multiple Myeloma · United States, Australia, Canada and more | 1 | Active, not recruiting | Jun 2, 2025 | 118 |
| NCT03848845Multiple Myeloma · United States, Canada, Germany and more | 2 | Completed | Oct 18, 2021 | 41 |
| NCT02064387Multiple Myeloma · United States, Canada, United Kingdom | 1 | Completed | Aug 31, 2018 | 79 |
How it is read
Names in the registry
- “Belantamab mafodotin”, 22 entries
- “Belantamab Mafodotin”, 1 entry
- “belantamab mafodotin”, 1 entry
- “GSK2857916”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 24 studies
- Amyloidosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.